ERBB2 and neoplasm: MEDI4276 ADC demonstrated effective and specific anti-tumor activity in HER2-expressing cancer models in vivo, and anti-PD-L1 therapy significantly augmented the therapeutic efficacy of MEDI4276 ADC (Figure 5A).